TEVA-IPRATROPIUM STERINEBS 250 MCG — DIN 02216221
IPRATROPIUM BROMIDE : 250 MCG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-IPRATROPIUM STERINEBS?
TEVA-IPRATROPIUM STERINEBS 250 MCG contains IPRATROPIUM BROMIDE : 250 MCG. It is listed in the Health Canada Drug Product Database under DIN 02216221, held by TEVA CANADA LIMITED, supplied as SOLUTION for INHALATION administration. Health Canada currently lists it as marketed, status dated 12-Jul-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-IPRATROPIUM STERINEBS used for?
As a bronchodilator for the maintenance treatment of bronchospasm associated with acute exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in adults. As a bronchodilator for the treatment of acute exacerbations of COPD in adults. When used concomitantly with an inhaled beta2-adrenergic agonist, such as salbutamol, for the treatment of acute bronchospasm due to asthma in patients 5 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Ipratropium Bromide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Ipratropium Bromide, across 30 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PHARMASCIENCE INC | 5 | 4 | PMS-IPRATROPIUM | Sourceable in Canada |
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 5 | 1 | ATROVENT, ATROVENT HFA, ATROVENT NASAL AEROSOL 20MCG/AEM, ATROVENT UDV 125MCG/ML, ATROVENT UDV SOL INH 250MCG/ML | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 1 | RATIO-IPRATROPIUM UDV, TEVA-IPRATROPIUM STERINEBS | Sourceable in Canada |
| AA PHARMA INC | 1 | 1 | AA-IPRAVENT | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP IPRATROPIUM HFA | Sourceable in Canada |
| DOMINION PHARMACAL | 4 | 0 | DOM-IPRATROPIUM 125 MCG/ML, DOM-IPRATROPIUM 250 MCG/ML (1 ML), DOM-IPRATROPIUM 250 MCG/ML (2 ML), DOM-IPRATROPIUM 250 MCG/ML (20 ML) | No marketed DIN |
| PHARMEL INC | 4 | 0 | PHL-IPRATROPIUM, PHL-IPRATROPIUM - 1ML POLYNEB, PHL-IPRATROPIUM - 20ML, PHL-IPRATROPIUM - 2ML POLYNEB | No marketed DIN |
| APOTEX INC | 2 | 0 | APO-IPRAVENT STERULES | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | NOVO-IPRAMIDE - LIQ 0.25MG/ML | No marketed DIN |
| NU-PHARM INC | 1 | 0 | NU-IPRATROPIUM PLASTIC AMPULES 250 MCG/ML | No marketed DIN |
| PENTAPHARM LTD. | 1 | 0 | PENTA-IPRATROPIUM BROMIDE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 1 | 0 | RATIO-IPRATROPIUM INHALATION SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | INHALATION |
| Pack configuration (monograph) | 500 mcg/2 mL is provided in cartons of 10 vials. 250 mcg/mL is provided in cartons of 20 vials. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ipratropium Bromide |
|---|---|
| ATC code | R03BB01 |
| AHFS class | 12:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02216221 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2216221 |
| Brand name | TEVA-IPRATROPIUM STERINEBS |
| Generic / active ingredient | IPRATROPIUM BROMIDE : 250 MCG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | R03BB01 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03BB |
| Current status | MARKETED |
| Status date | 12-Jul-2012 |
| Original market date | 1998-03-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Ipratropium Bromide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by JUNO PHARMACEUTICALS CORP., last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 30 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-IPRAVENT | 250 MCG | SOLUTION | AA PHARMA INC | MARKETED | 02126222 |
| ATROVENT HFA | 20 MCG | METERED-DOSE AEROSOL | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | 02247686 |
| JAMP IPRATROPIUM HFA | 20 MCG | METERED-DOSE AEROSOL | JAMP PHARMA CORPORATION | MARKETED | 02542587 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02231245 |
| PMS-IPRATROPIUM | 21 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02239627 |
| PMS-IPRATROPIUM | 250 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02231244 |
| PMS-IPRATROPIUM | 125 MCG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02231135 |
| APO-IPRAVENT STERULES | 250 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | 02231494 |
| APO-IPRAVENT STERULES | 125 MCG | SOLUTION | APOTEX INC | CANCELLED POST MARKET | 02243827 |
| ATROVENT | 250 MCG | SOLUTION | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 00731439 |
2 · Same class — other molecules in ATC R03BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ipratropium Bromide | AA-IPRAVENT · APO-IPRAVENT STERULES · ATROVENT · ATROVENT HFA · +20 more | 30 | 8 | Yes |
| Tiotropium Bromide | APO-TIOTROPIUM · LUPIN-TIOTROPIUM · SPIRIVA · SPIRIVA RESPIMAT | 4 | 4 | Yes |
| Aclidinium Bromide | TUDORZA GENUAIR | 1 | 1 | Yes |
| Glycopyrronium Bromide | SEEBRI BREEZHALER | 1 | 1 | Yes |
| Umeclidinium Bromide | INCRUSE ELLIPTA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03BA | Beclometasone · Budesonide · Ciclesonide · Flunisolide · Fluticasone · +3 more | 66 | 33 |
| R03BC | Cromoglicic Acid · Nedocromil | 11 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.